P Selectin Human
Single band on Western Blot.
THE BioTek's products are furnished for LABORATORY RESEARCH USE ONLY. The product may not be used as drugs, agricultural or pesticidal products, food additives or household chemicals.
Description
Product Specs
Product Science Overview
P-selectin is stored in the α-granules of platelets and Weibel-Palade bodies of endothelial cells . Upon activation by inflammatory stimuli, P-selectin is rapidly translocated to the cell surface . The protein consists of an extracellular domain, a single transmembrane domain, and a short cytoplasmic tail . The extracellular domain is responsible for binding to its ligand, P-selectin glycoprotein ligand-1 (PSGL-1), which is expressed on the surface of leukocytes .
P-selectin mediates the initial interaction between leukocytes and endothelial cells, a process known as "capture and rolling" . This interaction is essential for the recruitment of leukocytes to sites of injury or infection, facilitating their migration into tissues where they can combat pathogens .
While P-selectin is vital for normal immune function, its dysregulation can contribute to various pathological conditions. Sustained expression of P-selectin has been implicated in diseases such as venous thromboembolism, cardiovascular disease, stroke, metabolic syndrome, and sickle cell disease . The interaction between P-selectin and PSGL-1 can lead to maladaptive inflammatory and thrombotic responses, making it a target for therapeutic intervention .
Recombinant P-selectin is produced using Chinese Hamster Ovary (CHO) cells and is used in various research applications . The recombinant form retains the functional properties of the native protein, allowing researchers to study its role in cell adhesion, inflammation, and disease processes . It is often used in assays to measure the adhesion of leukocytes to endothelial cells, providing insights into the mechanisms of immune response and inflammation .
Given its central role in inflammation and thrombosis, P-selectin is a promising target for drug development. Inhibitors of the P-selectin/PSGL-1 pathway are being explored as potential treatments for diseases characterized by excessive inflammation and thrombosis . Both biologic and small-molecule inhibitors are under investigation, with some showing promise in preclinical and clinical trials .
